Abstract:Abstract Abstract 4529 Engraftment failure is a rare but life-threatening complication of hematopoietic stem cell transplantation. The treatment of this condition is often challenging. We firstly reported haploidentical donor stem cells transplantation resulted in hematological reconstitution and long-time disease-free survival in a patient who developed engraftment failure after unrelated donor allogeneic stem cell transplantation and failure rescue treatment by re-infusion of autologous “back-up” stem cells. The 39-years-old male patient with acute myeloid leukemia(AML)-M2a achieved complete remission (CR) after one course of induction chemotherapy. He entered a lasting CR with 7 courses post-remission consolidation therapy and decided to receive unrelated donor allogeniec stem cell transplantation. In case of engraftment failure after allo-HSCT, autologous “back-up” cells were harvested after the last course chemotherapy (IDA 15 mg on days 1–2, 10 mg on day 3, Ara-c 300 mg on days 1–3, 200 mg on day 4), and mobilized with G-CSF 5 mg/kg/day for 5 days. The “back-up” cells consisting of 9.94×106/kg CD34+ cells were cryopreservated in liquid nitrogen. Fifteen months after de novo AML, the patient received a myeloablative conditioning regimen of busulfan and cyclophosphamide (busulfan 3.2 mg/kg/day on days -7 to -4, and cyclophosphamide 60 mg/kg/day on days -3 to -2), and an infusion of unrelated allogeneic peripheral stem cells from the Chinese Marrow Donor Program with a HLA-Cw allele mismatch on day 0. The graft contained 11.07×108/kg nucleated cells and 6.35×106/kg CD34+ cells. Pancytopenia was continuously observed during 28 days after transplantation and short tandem repeat-polymerase chain reaction (STR-PCR) analysis showed no donor chimera. As a rescue attempt for graft failure, cryopreservated autologous cells were re-infused on day +28. Unfortunately, pancytopenia was still continuously observed during 23 days after re-infused of “back-up” cells(51 days after unrelated transplantation), and bone marrow examination revealed severe bone marrow hypoplasia. On day +57 and +58 after unrelated transplantation, bone marrow cells containing 2.1×106/kg CD34+ stem cells and peripheral blood cells containing 2.81×106/kg CD34+ stem cells from a haploidentical donor sister (HLA matched in 5/10 alleles by high-resolution genotyping) were infused respectively after reduced-intensity conditioning with fludarabine and ATG (fludarabine 30mg/m2/d on day -5 to -1, ATG 100mg/d on day -4 to -1). Absolute neutrophil count >0.5×109/L was documented on day 12 after haploidentical transplantation. He achieved platelets count >20×109/L on day 28 after haploidentical transplantation. Twenty-nine days after haploidentical transplantation, bone marrow examination showed reconstitution and STR-PCR analysis indicated complete donor chimera. No grades III -IV aGVHD, extensive chronic GVHD, and severe infection after transplantation were observed. Recurrent bone marrow aspiration examinations showed the patient had been in CR. The patient remained alive during a 18-month follow-up after haploidentical transplantation. Our experience suggests that combined haploidentical donor BM and PBSC transplantation after Flu- and ATG-based conditioning could provide an effective therapeutic strategy for engraftment failure after unrelated allo-HSCT in adult patients. Considering the accessibility of haploidentical donors, haploidentical transplantation has the potential to act as a first-line choice for salvage therapy. Disclosures: No relevant conflicts of interest to declare.

Treatment of Acute Leukemia During Pregnancy by Haploidentical Father Hematopoietic Stem Cell Combined Haploidentical Umbilical Cord Blood Transplantation and Review of the Literature

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Haploidentical Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Engraftment Failure after Unrelated and Autologous Cell Transplantation.

Treatment and prognosis analysis of acute leukemia patients during pregnancy

Successful Treatment of Acute Myelocytic Leukemia in Pregnancy Complicated with Lung Abscess

Successful Pregnancy and Childbirth in a Patient with Acute Lymphoblastic Leukaemia after Busulfan-Based Myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation: a Case Report

Twin Pregnancy and Childbirth after Reduced-intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation Combined with Imatinib Mesylate for Chronic Myeloid Leukaemia: Case Report and Literature Review

Unrelated umbilical cord blood can improve the prognosis of haploidentical hematopoietic stem cell transplantation

Pretreatment of unrelated umbilical cord blood transplantation without antithymocyte globulin for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia: follow-up evaluation of 306 cases

Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis

Treatment Of Acute Leukaemia With Unmanipulated Hla-Mis-Matched/Haploidentical Blood And Bone Marrow Transplantation

Maternal and Fetal Outcomes of Acute Leukemia in Pregnancy: A Retrospective Study of 52 Patients

Outcomes in pregnant women with leukemia and their offsprings

[Efficacy and safety analysis of umbilical cord blood combined with haploid hematopoietic stem cell transplantation in the treatment of malignant hematological malignancies]

HLA-haploidentical Peripheral Blood Hematopoietic Cell Transplantation in Combination with Third-Party Umbilical Cord Blood Transfusion for Hematologic Malignancies

[Clinical Observation on Haploid Hematopoietic Stem Cells Combined with Umbilical Cord Blood Double Transplantation for Aplastic Anaemia in Children]

Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study

Clinical analysis of 23 pregnant women with leukemia

Haploidentical Hematopoietic Stem Cell Transplantation Without In Vitro T-Cell Depletion For The Chronic Myeloid Leukemia: Improved Outcomes In Patients With Accelerated Phase And Blast Crisis Phase

Haploidentical stem cell transplantation for the treatment of leukemia: current status.